Satisfai Health Inc., a Canada-based medical solutions provider specializing in AI applications in Gastroenterology and GI Endoscopy, has entered into an exclusive development license with Oxford University Innovation Limited (OUI). This collaboration focuses on a novel digital solution developed by the Oxford Translational Gastroenterology Unit and Biomedical Engineering Department for assessing Barrett’s Oesophagus, a precancerous condition. Satisfai aims to further this work for clinical use. The technology was initially evaluated in a pilot study supported by Ludwig Cancer Research and the NIHR Oxford Biomedical Research Centre. Satisfai already has an AI-based solution, Veritai, for detecting dysplasia in Barrett’s Oesophagus. The…
Author: Abhay Panchal
Alimentiv Inc., Satisfai Health, Inc, and Virgo Surgical Video Solutions, Inc. have formed a strategic partnership aimed at transforming the clinical trial landscape for Inflammatory Bowel Disease (IBD) and related gastrointestinal (GI) conditions. The collaboration will focus on central reading, data capture, decision support, and patient recruitment. Satisfai Health, a global frontrunner in AI solutions for gastroenterology, and Virgo, a leader in endoscopy video capture technology, will combine their expertise with Alimentiv, a top Contract Research Organization (CRO) in gastroenterology. The goal is to harness the power of AI-driven precision imaging in GI clinical trials. Jeff Smith, CEO of Alimentiv,…
The FDA has revised the label for Ozempic, a medication used for diabetes and weight loss management, to include warnings about potential risks. The label now highlights the possibility of ileus (intestinal blockage) and an increased risk of hypoglycemia when Ozempic is used alongside insulin or insulin secretagogues. Glucagon-like peptide-1 (GLP-1) receptor agonists, which include semaglutide (the active ingredient in Ozempic), have been associated with gastrointestinal side effects like abdominal pain, constipation, diarrhea, nausea, and vomiting. The decision to update the label followed reports of patients developing ileus while on Ozempic. The FDA also emphasized the potential for hypoglycemia, especially…
Welcome to Impact Factor, your weekly dose of commentary on a new medical study. I’m Dr F. Perry Wilson of the Yale School of Medicine. If you run into a healthcare provider these days and ask, “How are you doing?” you’re likely to get a response like this one: “You know, hanging in there.” You smile and move on. But it may be time to go a step further. If you ask that next question — “No, really, how are you doing?” Well, you might need to carve out some time. It’s been a rough few years for those of…
Mayo Clinic and Microsoft have announced a collaboration where Mayo Clinic will be among the first health systems to deploy Microsoft 365 Copilot, a generative AI platform. This partnership is part of the Microsoft 365 Copilot Early Access Program. The program allows Mayo Clinic’s clinicians and staff to test AI technology that integrates large language models with Microsoft 365 apps such as calendars, emails, chats, and documents. The aim is to enhance productivity and reduce the administrative tasks that divert attention from patient care. Mayo Clinic believes that these generative AI applications can assist its medical professionals in automating tasks…
Intercept Pharmaceuticals, a company that once led the race for a NASH drug, is set to be acquired by Italian firm Alfasigma for $794 million. Alfasigma will pay $19 per Intercept share, marking an 82% premium over Intercept’s closing stock price prior to the announcement. Intercept’s primary asset, obeticholic acid, was approved by the FDA in 2016 as a treatment for primary biliary cholangitis under the brand name Ocaliva. The company had hoped that the drug could also treat NASH, a more common liver disorder. However, after the FDA rejected its application twice, Intercept decided to halt its NASH efforts…
Harbinger Health, a company focused on early cancer detection, has secured a significant funding of $140 million in a series B financing round. The company is developing a range of liquid biopsy tests and a software program to analyze blood samples for early signs of cancer. The funding was led by Flagship Pioneering, which had previously brought Harbinger out of stealth in 2021, and saw participation from new investors including Pictet, Partners Investment, and M&G Investments’ Catalyst fund. Key Insights:
Dr. Aasma Shaukat, a gastroenterologist and researcher in colon cancer screening, discusses the conflicting colorectal cancer (CRC) screening recommendations. The American College of Physicians (ACP) recently proposed CRC screening starting at age 50, using fecal occult blood-based testing every 2 years, and flexible sigmoidoscopy every 10 years or colonoscopy every 10 years. This contrasts with other major guidelines, which recommend initiating screening at age 45. The discrepancy arises from differing interpretations of the same evidence, with some emphasizing the rising CRC incidence in those under 50, while others point to the lack of randomized controlled trials for this age group.…
Amazon’s healthcare initiatives can combine Anthropic models with existing healthcare LLMs to integrate AI into healthcare initiatives like Amazon Clinic, One Medical and Pillpack.
Patients with confirmed nonerosive gastroesophageal reflux disease (GERD) are not at greater risk for esophageal cancer compared with the general population and are unlikely to need additional endoscopic monitoring for cancer, new research suggests. By contrast, patients with erosive disease had more than double the incidence of esophageal cancer. “We expected a less-strong association with cancer among patients with nonerosive GERD compared to those with erosive GERD, [and] the results do make sense in view of the fact that the nonerosive GERD patients had normal esophageal mucosa at endoscopy,” Jesper Lagergren, MD, PhD, of Karolinska Institutet, Stockholm, Sweden, told Medscape…